Basilea Pharmaceutica (BPMUF)
(Delayed Data from OTC)
$47.00 USD
0.00 (0.00%)
Updated Jul 17, 2024 02:00 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
Brokerage Reports
Basilea Pharmaceutica AG [BPMUF]
Reports for Purchase
Showing records 1 - 20 ( 73 total )
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Cresemba milestone payments continue to roll in
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Need for innovation against severe infections
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Capital Markets Day Highlights Portfolio; CARB-X Grant; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
CARB-X grant for preclinical programs
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Zevtera crosses key US regulatory hurdle
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Zevtera Approved in U.S. for Three Uses; Raising PT to CHF94
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Strong Cresemba traction triggers milestone payment
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Strong close to FY23 with another milestone payment
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Pipeline Overhauled; Debt Repayment Accelerated; Modulating PT to CHF85
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Antibiotic addition to further replenish pipeline
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Incremental acquisition to arsenal; new guidance
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Growth pivot with potential antibacterial addition
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
License Option Inked on Novel Antibacterial Agent Tonabacase; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Antifungal addition to bolster pipeline
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Novel Antifungal Acquired, Bolstering Clinical Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
New data support FDA application for ceftobiprole
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
FDA accepts New Drug Application for ceftobiprole
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Basilea Pharmaceutica AG
Industry: Medical - Biomedical and Genetics
Ceftobiprole New Drug Application Accepted for FDA Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R